UCB

Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...

SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...

BRUSSELS, Belgium, June 17, 2026 UCB has announced the publication of two significant peer-reviewed studies in Brain Communications demonstrating...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

SAN DIEGO, CALIFORNIA, May 03, 2026 UCB has announced a definitive agreement to acquire Candid Therapeutics in a transaction...

BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...

Brussels, Belgium & Atlanta, Georgia – March 24, 2026 Strategic Biologics Expansion to Strengthen Global Supply In a major...